Eli Lilly’s diabetes drug Mounjaro (tirzepatide) has made waves globally, gaining attention not only for its ability to control blood sugar but also for its significant weight-loss effects. Recently launched in India, the drug has been widely used in the United States since its FDA approval in May 2022. However, while many users praise its benefits, concerns over potential side effects are growing.
Mounjaro’s Promise: Diabetes Control and Weight Loss
Mounjaro, a once-weekly injectable medication, is a dual agonist targeting both GLP-1 and GIP receptors. This mechanism enhances insulin secretion, regulates blood sugar, and slows digestion, leading to reduced appetite and weight loss. Clinical trials have shown that patients using the highest dose (15 mg) lost an average of 21.8 kg over 72 weeks, with even lower doses showing significant weight reduction.
Public Reception in the United States
Mounjaro has been embraced by many in the U.S., especially those seeking weight-loss alternatives to drugs like Ozempic and Wegovy. Reviews on Drugs.com give the drug an 8.6/10 rating, with around 80% of users reporting positive experiences, citing improved blood sugar control and significant weight reduction.
Celebrity endorsements have also fueled interest. Comedian Rosie O’Donnell shared her positive experience with Mounjaro, highlighting its effectiveness in helping her lose weight and improve her overall health (People).
Concerns and Controversies
Despite its success, Mounjaro has not been free from controversy.
- Vision Problems: Reports have emerged linking GLP-1 receptor drugs, including Mounjaro, to sudden vision loss caused by non-arteritic anterior ischemic optic neuropathy (NAION). Some affected users have taken legal action, claiming insufficient warnings about these risks (New York Post).
- Mental Health Effects: Some patients report experiencing anxiety, insomnia, and anhedonia (loss of ability to feel pleasure) after significant weight loss on Mounjaro. Experts suggest that drastic weight changes may impact mental well-being, requiring close monitoring (Verywell Mind).
India’s Entry into the Mounjaro Market
Eli Lilly recently launched Mounjaro in India, where diabetes and obesity are on the rise. The drug is priced at ₹3,500 for a 2.5 mg vial and ₹4,375 for a 5 mg vial, bringing the monthly treatment cost to approximately ₹14,000–₹17,500. With Novo Nordisk planning to introduce Wegovy by 2026 and Indian pharmaceutical giants developing their own alternatives, competition in the Indian market is expected to intensify.
Mounjaro represents a breakthrough in diabetes management and weight loss, but it is not without risks. While many users praise its effectiveness, concerns over vision problems and mental health effects highlight the need for caution. As its use expands globally, including in India, continued research and monitoring will be crucial in determining its long-term safety and efficacy.
